Explore evidence

86.6 %The M36I mutation was identified in 86.6% of the 142 HIV-1 isolates in the protease gene.

CamerounVIH/sidapublished 2000Journal of Clinical MicrobiologyOpenAlexdocument of 19 observations

57 patients57 of the 74 patients with antiretroviral drug resistance were also resistant to nucleoside reverse-transcriptase inhibitors.

CamerounVIH/sidaobserved 2013-2014published 2016Open Forum Infectious DiseasesOpenAlexdocument of 5 observationsDOI 10.1093/ofid/ofw233

0.5 %The vertical transmission rate was 0.5% (2/439) among infants born to mothers who commenced HAART before pregnancy.

CamerounVIH/sidaobserved November 2007 to October 2010published 2019Paediatrics and international child healthPubMeddocument of 7 observations

41 sampleForty-one HIV-1-positive samples were analyzed from military personnel in Malabo, Equatorial Guinea.

CamerounVIH/sidapublished 2010AIDS research and human retroviruseseurope_pmcdocument of 4 observationsDOI 10.1089/aid.2010.0046

1,083 SFU/10^6 PBMCThe median T cell response to Gag was 1083 spot forming units per 10^6 PBMC.

CamerounVIH/sidapublished 2009RetrovirologyOpenAlexdocument of 6 observationsDOI 10.1186/1742-4690-6-s3-p273

2.3 %46 patients (2.3%) in the health center group had no follow-up visit.

CamerounVIH/sidapublished 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

20 %In 2010, 20% of 40 ART sites in Cameroon attained the target for patient lost to follow-up (target ≤ 20%).

CamerounVIH/sidaobserved 2010published 2012PLoS ONEOpenAlexdocument of 5 observationsDOI 10.1371/journal.pone.0036777

The prevalence of diabetes mellitus is higher in HIV-positive persons compared to the general population.

Cameroundiabète (non précisé) · VIH/sidapublished 2018Current diabetes reportseurope_pmcdocument of 2 observations

-0.403 correlation_coefficientThe magnitude of the total T cell response correlated inversely with CD4 count (r = -0.4026, p = 0.0165).

CamerounVIH/sidapublished 2009RetrovirologyOpenAlexdocument of 6 observationsDOI 10.1186/1742-4690-6-s3-p273

36.6 %Among those testing HIV-positive, 36.6% were enrolled into HIV care at their nearest clinics.

CamerounVIH/sidapublished 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

1.6 monthsMedian time to antiretroviral treatment initiation was 1.6 months among 847 HIV-positive patients in Cameroon in 2014.

CamerounVIH/sidaobserved 2014published 2020Health Policy and PlanningOpenAlexdocument of 6 observationsDOI 10.1093/heapol/czaa153

72.1 %Viral suppression in the ART 12-24 group was 72.1% overall.

CamerounVIH/sidapublished 2018EClinicalMedicineeurope_pmcdocument of 6 observations

142 isolatesAmong 142 HIV-1 isolates, there were 9 subtype A, 13 subtype B, 2 subtype C, 5 subtype D, 2 subtype F1, 9 subtype F2, 4 subtype G, 5 subtype J, 2 subtype K, 3 subtype CRF01-AE, 67 subtype CRF02-AG, and 17 unclassified isolates.

CamerounVIH/sidapublished 2000Journal of Clinical MicrobiologyOpenAlexdocument of 19 observations

46 %46% of HIV-positive adults were newly diagnosed.

CamerounVIH/sidapublished 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

25 %One in four pregnant women on HAART, without current indications of treatment failure, had a detectable viral load.

CamerounVIH/sidapublished 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

12.6 %The L63P mutation was identified in 12.6% of the 142 HIV-1 isolates in the protease gene.

CamerounVIH/sidapublished 2000Journal of Clinical MicrobiologyOpenAlexdocument of 19 observations

AIDS and malaria epidemics afflict the population of Cameroon.

Camerounpaludisme · VIH/sidapublished 2005Tissue AntigensOpenAlexdocument of 15 observations

0.5 log10_HIV_RNA_copies_per_mlFor samples infected with subtype B, C, and D and tested with version 1.5, only a slight increase in viral load was observed (<0.5 log10).

CamerounVIH/sidapublished 1999Journal of Clinical MicrobiologyOpenAlexdocument of 6 observationsDOI 10.1128/jcm.37.1.110-116.1999

Clustering of metabolic disorders ≥1 component of the metabolic syndrome increased with duration of highly active antiretroviral therapy (HAART) in HIV-infected Cameroonians.

CamerounVIH/sidapublished 2013Diabetes & metabolismeurope_pmcdocument of 12 observations

3 specimensPhylogenetic analysis of the gp41 region of 123 HIV-1-seropositive specimens from Cameroon showed that 3 were group O.

CamerounVIH/sidapublished 2000AIDS Research and Human RetrovirusesOpenAlexdocument of 7 observations

5 %The prevalence of the 77I substitution in protease sequences was 5% (3/57) among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublished 2011AIDS Research and Human RetrovirusesOpenAlexdocument of 24 observations

1.9 %The vertical transmission rate was 1.9% (6/321) among infants born to mothers who commenced HAART during pregnancy.

CamerounVIH/sidaobserved November 2007 to October 2010published 2019Paediatrics and international child healthPubMeddocument of 7 observations

12.5 %Among 128 patients routinely receiving highly active antiretroviral therapy in an HIV/AIDS outpatient clinic in Cameroon, 12.5% had resistance to nucleoside reverse transcriptase inhibitors (NRTIs).

CamerounVIH/sidapublished 2006Emerging infectious diseasesOpenAlexdocument of 4 observationsDOI 10.3201/eid1206.050860

89 %Among 36 HIV-1 infected blood donors in Cameroon, 32 (89%) responded to at least one peptide pool in the IFNγ ELISPOT assay.

CamerounVIH/sidapublished 2009RetrovirologyOpenAlexdocument of 6 observationsDOI 10.1186/1742-4690-6-s3-p273

4.3 %Pretreatment HIV drug resistance (PDR) prevalence among ART initiators in rural areas of Cameroon was 4.3% (95% CI 1.2%–14.3%).

CamerounVIH/sidaobserved 2015published 2018Journal of Antimicrobial ChemotherapyOpenAlexdocument of 12 observationsDOI 10.1093/jac/dky221